Tag: Jeremy Wohlwend
MIT researchers develop AI tool to improve flu vaccine strain selection
Every year, global health experts are faced with a high-stakes decision: Which influenza strains should go into the next seasonal vaccine? The choice must be made months in advance, long before flu season even begins, and it can often feel like a race against the clock. If the selected strains match those that circulate, the vaccine will likely be highly effective. But if the prediction is off, protection can drop significantly, leading to (potentially preventable) illness and strain on health care systems. Learn more
Boltz-2 Released to Democratize AI Molecular Modeling for Drug Discovery
Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding affinity at newfound speed and accuracy to democratize commercial drug discovery. The model is available under the highly permissive MIT license, which allows commercial drug developers to use the model internally and apply their own proprietary data. Learn more
The Prototype: This AI Model Could Make It Faster To Find New Medicines
The 2024 Nobel Prize in Chemistry was awarded in part to Deepmind’s Demis Hassabis and John Jumper for the development of AlphaFold–an AI model that predicts the structure of proteins, the complex chemicals essential to making our bodies work. Since its inception, this model and others like it have been put to use in laboratories around the world, enabling new biological discoveries.Now a team from MIT and pharmaceutical company Recursion, with support from Cancer Grand Challenges, have developed a tool that takes these principles further–and may help researchers find new medicines more quickly. Called Boltz-2, this open-source generative AI model can not only predict the structure of proteins, it can also predict its binding affinity–that is, how well a potential drug is able to interact with that protein. This is crucial in the early stages of developing a new medicine. Learn more
MIT researchers introduce Boltz-1, a fully open-source model for predicting biomolecular structures
MIT scientists have released a powerful, open-source AI model, called Boltz-1, that could significantly accelerate biomedical research and drug development. Developed by a team of researchers in the MIT Jameel Clinic for Machine Learning in Health, Boltz-1 is the first fully open-source model that achieves state-of-the-art performance at the level of AlphaFold3, the model from Google DeepMind that predicts the 3D structures of proteins and other biological molecules. MIT graduate students Jeremy Wohlwend and Gabriele Corso were the lead developers of Boltz-1, along with MIT Jameel Clinic Research Affiliate Saro Passaro and MIT professors of electrical engineering and computer science Regina Barzilay and Tommi Jaakkola. Wohlwend and Corso presented the model at a Dec. 5 event at MIT’s Stata Center, where they said their ultimate goal is to foster global collaboration, accelerate discoveries, and provide a robust platform for advancing biomolecular modeling. Learn more
9 new breakthroughs in the fight against cancer
Lung cancer kills more people in the US yearly than the next three deadliest cancers combined. It's notoriously hard to detect the early stages of the disease with X-rays and scans alone. However, MIT scientists have developed an AI learning model to predict a person's likelihood of developing lung cancer up to six years in advance via a low-dose CT scan. Learn more